BTIG and H.C. Wainwright & Co. are acting as co-lead managers with D. Boral Capital acting as co-manager for the offering.

According to relationship and mental health experts, "bright siding" happens all the time, and it's something people often do with good intentions. Still, it can have disastrous consequences by ...

D. Boral Capital keeps a Buy rating on Anavex Life Sciences (AVXL) with a $46 price target after Cassava Sciences’ (SAVA) Phase 3 trial for simufilam in mild-to-moderate Alzheimer’s disease ...

D. Boral Capital downgraded Citius Pharmaceuticals (CTXR) to Hold from Buy without a price target following the company’s announcement of a 1-for-25 reverse stock split. The reverse is partly a ...